PARP1 and anemia: Exploring and comparing adverse events between PARP inhibitors (niraparib, olaparib, and rucaparib) found that hematologic toxicity was common across the PARP-inhibitors drug class, with anemia being the most common and likely associated with activity against PARP 2.